Cutaneous drug reactions are adverse reactions to medications that may present with different clinical features, ranging from localized to generalized lesions. In this report we describe a case of an unusual drug reaction, resembling the morphology of Sweet syndrome lesions. The patient had a psychiatric illness and was using thioridazine hydrochloride for one year. He developed infiltrated and...

AIM To evaluate the utility of patch test and cross-sensitivity patterns in patients with adverse cutaneous drug reactions (ACDR) from common anticonvulsants. METHODS Twenty-four (M:F = 13:11) patients aged 18-75 years with ACDR from anticonvulsants were patch tested 3-27 mo after complete recovery using carbamazepine, phenytoin, phenobarbitone, lamotrigine, and sodium valproate in 10%, 20% a...

Background Aromatic (lamotrigin, carbamazepine, phenobarbital) and non aromatic antiepileptic (valproat, topiramate) drugs are frequently associated with hypersensitivity reactions mainly cutaneous such as maculopapular exanthems and bullous and pustular eruptions on the basis of their clinical, cellular and molecular pathophysiology. They usually occur more than 1 hour after the last drug admi...

stevens-johnson syndrome (sjs) and toxic epidermal necrolysis (ten) are severe adverse cutaneous reactions to drugs. we describe the case of a 19 year old patient with sjs/ten overlap syndrome, who developed severe interstitial pneumonia after she had received antiepileptic drugs. a cytomegalovirus infection was diagnosed by real time polymerase chain reaction (rt-pcr) detection on bronchoalveo...

PURPOSE Vemurafenib is a potent inhibitor of V600 mutant BRAF with significant impact on progression-free and overall survival in advanced melanoma. Cutaneous side effects are frequent. This single-center observational study investigates clinical and histological features of these class-specific cutaneous adverse reactions. PATIENTS AND METHODS Patients were all treated with Vemurafenib 960 m...

Imatinib mesylate (Gleevec™, STI571), a selective inhibitor of BCR-ABL, c-Kit, and platelet-derived factor receptor, has been used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors. Although its use has been associated with various adverse cutaneous reactions, pityriasis rosea-like drug eruptions are rare. Here, we report a case of pityriasis rosea-like drug erupti...